# Stanley Cohen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/stanley-cohen-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,007 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 68 |
| i10-index | 165 |
| Last Known Institution | Texas Health Dallas |
| OpenAlex ID | https://openalex.org/A5057538503 |
| ORCID iD | https://orcid.org/0000-0002-9226-979X |
| Works | 273 |

## Researcher papers

- [The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment](https://scholariq.org/papers/the-premier-study-a-multicenter-randomized-double-blind-clinical-trial-of/)
- [Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks](https://scholariq.org/papers/rituximab-for-rheumatoid-arthritis-refractory-to-anti-tumor-necrosis-factor/)
- [Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis](https://scholariq.org/papers/tofacitinib-or-adalimumab-versus-placebo-in-rheumatoid-arthritis/)
- [Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study](https://scholariq.org/papers/tofacitinib-cp-690-550-in-patients-with-rheumatoid-arthritis-receiving/)
- [A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone](https://scholariq.org/papers/a-phase-iib-dose-ranging-study-of-the-oral-jak-inhibitor-tofacitinib-cp-690-550/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

## Researcher university

- [Texas Health Dallas](https://scholariq.org/institutions/texas-health-dallas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.